A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: Dato-DXd|DRUG: Durvalumab|DRUG: Paclitaxel|DRUG: Nab-paclitaxel|DRUG: Gemcitabine|DRUG: Carboplatin|DRUG: Pembrolizumab
Sponsor: AstraZeneca
Collaborators: Daiichi Sankyo